XML 16 R4.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Development revenue:    
Government contracts and other $ 303 $ 6,998
Total development revenues 303 6,998
Operating expenses:    
Research and development 2,700 5,365
General and administrative 6,406 5,290
Total operating expenses 9,887 10,655
Operating loss (9,584) (3,657)
Other income (expense):    
Interest income 50 55
Interest expense (1,107) (1,855)
Change in fair value of liability instruments 2,400 3,407
Issuance cost of warrants 0 (1,233)
Total other expense 1,343 374
Loss from continuing operations (8,241) (3,283)
Loss from discontinued operations 0 (7,604)
Net loss (8,241) (10,887)
Loss from continuing operations (8,241) (3,283)
Beneficial conversion feature for convertible preferred stock 0 (554)
Net loss allocable to common stockholders - continuing operations (8,241) (3,837)
Net loss allocable to common stockholders - discontinued operations 0 (7,604)
Net loss allocable to common stockholders $ (8,241) $ (11,441)
Basic and diluted net loss per share attributable to common stockholders - continuing operations $ (1.86) $ (2.77)
Basic and diluted net loss per share attributable to common stockholders - discontinued operations 0 (5.49)
Net loss per share, basic and diluted $ (1.86) $ (8.27)
Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders 4,427,835 1,384,012
In Process Research and Development [Member] | Nano Tx Therapeutics [Member]    
Operating expenses:    
Research and development $ 781 $ 0